Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKVBL8)

Drug Name
Stenoparib Drug Info
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Cross-matching ID
PubChem CID
135565981
TTD Drug ID
DMKVBL8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Poly [ADP-ribose] polymerase 1 (PARP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nicotinamide DMUPE07 Acne vulgaris ED80 Approved [2]
KU-0058948 DMSA4HZ Ovarian cancer 2C73 Approved [3]
Niraparib Tosylate DMLPSWQ Fallopian tube cancer 2C74 Approved [4]
CC-486 DMTNQB0 Acute myeloid leukaemia 2A60 Phase 3 [5]
Nicaraven DMFBNA3 Cerebrovascular disease 8B2Z Phase 3 [6]
PMID27841036-Compound-37 DM0OVZ2 Ovarian cancer 2C73 Phase 2 [7]
AG140699 DMA9FKY Melanoma 2C30 Phase 2 [8]
AZD5305 DMW9R1C Prostate cancer 2C82.0 Phase 2 [9]
AMXI 5001 DMR9H6B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
NMS-03305293 DM2XIRW Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Tankyrase-2 (TNKS-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27841036-Compound-37 DM0OVZ2 Ovarian cancer 2C73 Phase 2 [7]
Drug(s) Targeting Tankyrase-1 (TNKS-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27841036-Compound-37 DM0OVZ2 Ovarian cancer 2C73 Phase 2 [7]
Drug(s) Targeting Poly [ADP-ribose] polymerase 2 (PARP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27841036-Compound-37 DM0OVZ2 Ovarian cancer 2C73 Phase 2 [7]
AMXI 5001 DMR9H6B Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC N. A. N. A. Patented [7]
Dihydrodiazepinocarbazolone derivative 1 DMC3IN2 N. A. N. A. Patented [7]
Tetra-cyclic pyridophthalazinone derivative 1 DMX2EFL N. A. N. A. Patented [7]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase 1 (PARP1) TTVDSZ0 PARP1_HUMAN Inhibitor [1]
Poly [ADP-ribose] polymerase 2 (PARP2) TTQ4V96 PARP2_HUMAN Inhibitor [1]
Tankyrase-1 (TNKS-1) TTVUSO7 TNKS1_HUMAN Inhibitor [1]
Tankyrase-2 (TNKS-2) TTFQI4H TNKS2_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of Allarity Therapeutics.
2 beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59.
3 Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3.
6 Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7.
7 PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382.
8 Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40.
9 Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736.
10 AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676.
11 NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843.